Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Alfresa HoldingsALFRY 75 EV-to-EBITDA is 2.82 as of Aug. 08, 2026, which is 48% below its 10-year median of 5.42. GuruFocus rates ALFRY with a GF Score™ of 75/100 and a GF Value™ of $16.19 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 99 Medical Distribution companies, Alfresa Holdings ranks better than 92.93% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Alfresa Holdings's enterprise value is $1,419 Mil.
Alfresa Holdings's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was $503 Mil. Therefore, Alfresa Holdings's EV-to-EBITDA for today is 2.82.
The historical rank and industry rank for Alfresa Holdings's EV-to-EBITDA or its related term are showing as below:
ALFRY'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 2.84 Med: 5.42 Max: 10.16
Current: 3.3
During the past 13 years, the highest EV-to-EBITDA of Alfresa Holdings was 10.16. The lowest was 2.84. And the median was 5.42.
ALFRY's EV-to-EBITDA is ranked better than 92.93% of 99
companies
in the Medical Distribution industry
Industry Median: 8.52
vs ALFRY: 3.30
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Alfresa Holdings's PE Ratio (TTM) for today is calculated as:
Alfresa Holdings's share price for today is $13.55.
Alfresa Holdings's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.494.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Alfresa Holdings's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Distribution subindustry, Alfresa Holdings's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alfresa Holdings EV-to-EBITDA vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Alfresa Holdings's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Alfresa Holdings's EV-to-EBITDA falls into.
Alfresa Holdings's current Enterprise Value is $1,419 Mil.
Alfresa Holdings's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $503 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alfresa Holdings (ALFRY) has a EV-to-EBITDA of 2.82 as of Aug. 08, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Alfresa Holdings. This is 48% below median its historical median of 5.42. Over the past decade, Alfresa Holdings' EV-to-EBITDA has ranged from 2.84 to 10.16. According to the industry distribution chart, Alfresa Holdings ranks #7 out of 99 companies in the Medical Distribution industry, placing it in the top 7.1%.
Is Alfresa Holdings' EV-to-EBITDA too high?
Alfresa Holdings' current EV-to-EBITDA of 2.82 is 48% below median its 10-year median of 5.42. Over the past 10 years, this metric has ranged from a low of 2.84 to a high of 10.16. The Medical Distribution industry median EV-to-EBITDA is 8.52. Alfresa Holdings' value of 2.82 is 66.9% below this industry median. Based on the distribution chart, Alfresa Holdings ranks #7 out of 99 companies in the Medical Distribution industry, which is in the top quartile — a strong position relative to peers. Overall, Alfresa Holdings has a GF Score™ of 75/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Alfresa Holdings' EV-to-EBITDA compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Alfresa Holdings ranks #7 out of 99 companies for EV-to-EBITDA. This places Alfresa Holdings in the top 7% of its industry — outperforming the majority of peers. The industry median EV-to-EBITDA is 8.52. Alfresa Holdings' value of 2.82 is 66.9% below this benchmark. Historically, Alfresa Holdings' own EV-to-EBITDA has ranged from 2.84 to 10.16 over the past decade. While the company's 10-year median is 5.42 vs. the industry median of 8.52, Alfresa Holdings has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Distribution company?
The median EV-to-EBITDA among Medical Distribution companies is 8.52, based on 99 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Alfresa Holdings's current EV-to-EBITDA of 2.82 is 66.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Alfresa Holdings. For the Medical Distribution industry, the median EV-to-EBITDA is 8.52 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Alfresa Holdings's current EV-to-EBITDA is 2.82, which is 48% below median its own 10-year median of 5.42. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alfresa Holdings stock overvalued right now?
Based on GuruFocus' analysis, Alfresa Holdings (ALFRY) is currently considered Modestly Undervalued. The stock's GF Value™ is $16.19, compared to a current price of $13.55 — trading 16.3% below its estimated fair value. The current EV-to-EBITDA is 2.82, which is 48% below median its 10-year median of 5.42 and 66.9% below the Medical Distribution industry median of 8.52. Alfresa Holdings' overall GF Score™ is 75/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Alfresa Holdings (ALFRY), the current EV-to-EBITDA is 2.82 as of Aug. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Alfresa Holdings (ALFRY) Overvalued in 2026?
Based on GuruFocus' analysis, Alfresa Holdings stock appears to be undervalued.
The current stock price of $13.55 is trading 16.3% below its estimated GF Value™ of $16.19.
GuruFocus considers Alfresa Holdings to be Modestly Undervalued.
Key valuation signals for ALFRY:
EV-to-EBITDA: 2.82 (48% below median its 10-year median of 5.42)
GF Value™: $16.19 vs. price of $13.55 (16.3% below fair value)
Industry Position: 66.9% below the Medical Distribution median (#7 of 99)
No single metric tells the full story. See the ALFRY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Alfresa Holdings Corp is engaged in the pharmaceutical distribution and related businesses. The company operates through four reportable segments: Wholesale business of medical drugs, Self-Medication Wholesale Business, Pharmaceutical Manufacturing Business, and Medical-Related Business. Its operations include the wholesale of ethical and over-the-counter pharmaceuticals, the manufacture and sale of pharmaceuticals, medical testing reagents, and medical equipment, as well as the operation of dispensing pharmacies.
75GF Score
Get the complete analysis for ALFRY
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ALFRY has been successfully added to your 
